Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPOCH Chemotherapy and Combivir/Interferon ALPHA-2a for HTLV-1 Associated T-Cell Non-Hodgkin's Lymphoma
NCT00041327Phase 2Completed
- Sponsor
- AIDS Malignancy Consortium
- Start
- Oct 2002
- Primary completion
- Dec 2006
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etoposide, prednisone, vincristine sulfate liposome injection, cyclophosphamide, pegylated liposomal doxorubicin and 3 more in adult T-cell leukemia-lymphoma (ATLL), sponsored by AIDS Malignancy Consortium. Primary endpoints: Objective Response Rate at 60 days, Duration of Response at 3 years and 2 more. Started Oct 2002; status: completed.
02
Drugs
etoposideprednisonevincristine sulfate liposome injectioncyclophosphamidepegylated liposomal doxorubicin
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on NCT00041327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00041327.